CA2276276A1 - Medicament destine au traitement du cancer - Google Patents
Medicament destine au traitement du cancer Download PDFInfo
- Publication number
- CA2276276A1 CA2276276A1 CA002276276A CA2276276A CA2276276A1 CA 2276276 A1 CA2276276 A1 CA 2276276A1 CA 002276276 A CA002276276 A CA 002276276A CA 2276276 A CA2276276 A CA 2276276A CA 2276276 A1 CA2276276 A1 CA 2276276A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- cancer
- kotshyi
- boss
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title claims abstract description 23
- 201000011510 cancer Diseases 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title abstract description 4
- 240000005523 Peganum harmala Species 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 5
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 4
- 241001529849 Dracocephalum Species 0.000 claims description 5
- 235000005126 Peganum harmala Nutrition 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003157 cancerolytic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 3
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1997/006155 WO1999024048A1 (fr) | 1997-11-06 | 1997-11-06 | Medicament destine au traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2276276A1 true CA2276276A1 (fr) | 1999-05-20 |
Family
ID=8166782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002276276A Abandoned CA2276276A1 (fr) | 1997-11-06 | 1997-11-06 | Medicament destine au traitement du cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0951291A1 (fr) |
JP (1) | JP2001514671A (fr) |
CA (1) | CA2276276A1 (fr) |
WO (1) | WO1999024048A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
JP5997156B2 (ja) * | 2010-08-24 | 2016-09-28 | ジーティーエックス・インコーポレイテッド | 癌の治療のための化合物 |
CN102286085B (zh) * | 2011-07-25 | 2014-06-11 | 新疆大学 | 一种骆驼蓬脂转移蛋白及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1034135A (zh) * | 1987-10-27 | 1989-07-26 | 新疆医学院第二附属医院 | 骆驼蓬种子浸膏的制备方法 |
CN1047528C (zh) * | 1993-11-18 | 1999-12-22 | 王世渝 | 一种骆驼蓬制剂 |
-
1997
- 1997-11-06 EP EP97948892A patent/EP0951291A1/fr not_active Withdrawn
- 1997-11-06 CA CA002276276A patent/CA2276276A1/fr not_active Abandoned
- 1997-11-06 JP JP52524399A patent/JP2001514671A/ja active Pending
- 1997-11-06 WO PCT/EP1997/006155 patent/WO1999024048A1/fr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1999024048A1 (fr) | 1999-05-20 |
EP0951291A1 (fr) | 1999-10-27 |
JP2001514671A (ja) | 2001-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ijaz et al. | Nigella sativa (Prophetic Medicine): A Review. | |
Ghosh | Tannins from foods to combat diseases | |
Namba | Maitake D-fraction: healing and preventive potential for cancer | |
US6395311B2 (en) | Multicomponent biological vehicle | |
US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
JPH0344048B2 (fr) | ||
US20090142419A1 (en) | Anti-inflammatory extract and agent and method for the production thereof | |
Chekka et al. | Momordica charantia: A natural medicinal plant | |
CA2700338C (fr) | Composition a base de plantes a activite immunostimulante, antitumorale et anti-sida, et procede de preparation de cette composition a base de plantes | |
CA2276276A1 (fr) | Medicament destine au traitement du cancer | |
Mohammed et al. | Evaluation of the effect of aqueous leaf extract of jute mallow corchorus olitorius on some biochemical parameters in alloxan-induced diabetic rats | |
KR20030055154A (ko) | 피부질환 치료용 조성물 및 그 제조방법 | |
US11357813B2 (en) | Composition comprising tannins | |
CN113209065B (zh) | 生物碱化合物在制备预防和/或治疗心脏损伤的产品中的用途 | |
CN102008470B (zh) | 复方制剂及其预防和治疗噪声性听力损伤的用途 | |
RU2408383C1 (ru) | Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты) | |
CN109731019B (zh) | 一种具有化疗增效作用的组合物,包括组成、制备及应用 | |
US20050182037A1 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
KR102028383B1 (ko) | 난청의 예방 또는 치료용 조성물 | |
CN111728985B (zh) | 一种以蛤蟆油为主要成分的组合物及其用途 | |
KR102007096B1 (ko) | 비스쿰 오발리포리움 추출물을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물 | |
JPH06199696A (ja) | 制癌・抗癌剤 | |
CN105343124A (zh) | 生肌长皮散 | |
WO2022264058A1 (fr) | Composition pour la prévention et/ou le traitement de maladies inflammatoires | |
RU2259205C1 (ru) | Лечебно-профилактическое средство при заболеванях мочеполовой системы у мужчин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |